IL6 and cancer: Furthermore, although we have identified significant activation of pro-cancer immune pathways, such as IL6-JAK-STAT3 and IFN-γ, in high-risk patients, along with a decrease in the infiltration levels of 19 critical immune cells—including CD8 + T cells and dendritic cells—in the tumor microenvironment, we have only begun to elucidate the malignant cycle between immune evasion and immune suppression.